Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1995-1999  (2)
  • Impfstoff gegen Varizellen  (1)
  • Key words Pertussis  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany (1998)
    Springer
    European journal of pediatrics 157 (1998), S. 395-401 
    Details
    ISSN: 1432-1076
    Keywords: Key words Pertussis ; Cost-effectiveness ; Acellular pertussis vaccine ; Whole-cell pertussis vaccine
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Acellular pertussis vaccines are less reactogenic than whole cell pertussis vaccines, but they are also more expensive. Based on simulation models, we compared the costs and effects of three alternative pertussis vaccination strategies in German children to ”no prevention”: (1) vaccination with whole-cell vaccine at 45% coverage (vaccine efficacy 90%), (2) vaccination with acellular vaccine at 45% coverage (vaccine efficacy 85%), and (3) vaccination with acellular vaccine at 90% coverage. In the two low coverage scenarios expected annual savings in direct medical costs through prevention of disease were larger for whole-cell than for acellular vaccination (252 vs 216 million DM, respectively). Direct costs for treating the more important adverse events induced by whole-cell vaccination (16.9 million DM annually) did not outweigh the higher direct costs of pertussis infections not prevented with the acellular vaccine and the higher price of the acellular vaccine. However, vaccination with acellular pertussis vaccine rapidly becomes as cost saving as vaccination with whole-cell vaccine as soon as vaccination coverage can be raised from 45% to 52.5% with acellular vaccine. Acellular vaccination is also the superior alternative when considering indirect cost savings resulting from reduction in work-loss due to adverse events. Conclusion In our simulations, the most cost-effective pertussis prevention strategy was the use of an effective whole-cell vaccine with a high coverage rate. Introduction of the more expensive acellular pertussis vaccines becomes cost saving if at least a 7.5% increase in coverage is achieved. If also non-medical indirect costs to parents resulting from vaccine associated side-effects are accounted for, acellular vaccines may be more cost-effective also in countries with already high whole-cell vaccine coverage.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004310050837
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Gegen Varizellen impfen? (1999)
    Springer
    Monatsschrift Kinderheilkunde 147 (1999), S. 626-633 
    Details
    ISSN: 1433-0474
    Keywords: Schlüsselwörter Varizellen ; Impfstoff gegen Varizellen ; Routineprüfung ; Indikationsimpfung ; Anwendung in Deutschland ; Key words Varicella ; Varicella vaccine ; Routine vaccination ; Vaccination of risk groups use in Germany
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Background: For more than ten years, a live, attenuated varicella vaccine is available. With the licensure of a temperature stable vaccine preparation in Germany in 1994, a cost reduction from DM 510,– to DM 99.50 was achieved with a general vaccine availability independent of special cooling requirements. In the United States, in Japan and in Southern Korea varicella vaccine is already in use for routine vaccination in the second year of life. In contrast, in Germany the recommendation for VZV-vaccination is restricted to patients at increased risk for varicella complications as well as for regular intimate contacts of such persons. Discussion: In this article a short review of varicella and zoster is given, the characteristics of the VZV-vaccine are described and the options for future use in Germany are discussed.
    Notes: Zusammenfassung Hintergrund: Seit mehr als 10 Jahren ist ein Lebendimpfstoff gegen Varizellen verfügbar. Mit Zulassung eines temperaturstabilen Präparats in Deutschland im Jahr 1994 sind die Kosten für eine Dosis von rund DM 510,– auf DM 99,50 gesunken, eine generelle Verfügbarkeit ist heute gewährleistet. In den Vereinigten Staaten von Amerika, in Japan und in Südkorea wird dieser Impfstoff routinemäßig und universell im Kleinkindesalter appliziert, in Deutschland dagegen wird er lediglich als Indikationsimpfung für Risikogruppen empfohlen. Diskussion: In diesem Artikel wird kurz die Varicella-Zoster-Virus(VZV)-Infektion beschrieben, danach werden die Charakteristika des VZV-Impfstoffs dargestellt. Die verschiedenen Möglichkeiten der Anwendung des VZV-Impfstoffs und deren jeweilige Folgen in Deutschland werden diskutiert.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001120050472
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...